Introduction
In pediatric patients, the unpleasant taste of a medicine is one of the commonest causes of treatment barrier (1), and the importance of building palatability into pediatric medicines is now recognized by the pharmaceutical industry (2) and the regulatory authorities (3, 4) .
However, there is no specific regulatory framework for palatability assessment, which has resulted in a lack of harmonization of taste evaluation methodologies applied in the development of pediatric medicines (5, 6) .
The simplest taste evaluation methods for peroral pediatric medicines is to determine the in vitro drug release profile of the medicines in simulated physiological fluids, the rationale being that only the freely soluble drug molecules can interact with taste receptors. While cheap and readily accessible, this method is better suited to solid medicines, not solution formulations, and provides a measure of taste only when human perception of the tastant is known to some extent (e.g. as a taste threshold concentration). Currently, there are no regulatory-defined parameters to simulate drug release in the oral cavity from medicines.
Published studies that have utilized the in vitro drug dissolution method to evaluate medicine palatability have employed a range of dissolution medium (water (7) to pH 6.8 phosphate buffer (8, 9) ), receptor fluid volume (10 ml (10) to 900 ml (8) ), and dissolution time (2 min (8, 9) to 5 min (7)).
Electronic taste evaluation may be a better alternative (11) as it can profile the taste characteristic of the drug molecule via an array of sensors (12) . Compared to in vivo models, electronic sensors also provide a more objective and consistent taste evaluation without incurring the ethical and safety concerns associated with using animal and human participants.
Electronic tongues are, however, limited by their application to assess only aqueous solutions, and the sensor sensitivity can be affected by formulation pH and excipients (13) . 4 An in vivo model that exploits the natural defense mechanism in most animals to avert bitter-tasting substances has also been developed for the palatability testing of medicines (14) .
Mildly water-deprived rats are presented with the liquid tastant, and an IC50 dose, defined as the tastant concentration that causes a 50% drop in licking frequency compared to water, is determined. This model is advocated for novel lead compounds whose toxicology has not been adequately elucidated to safeguard taste evaluation in humans. Products for evaluation by this method have to be liquid formulations of appropriate viscosity, and if they are suspensions, to have particles below a threshold diameter to enable the liquid formulations to flow freely through the sipping tube for the animals to lick. It is difficult to establish the accuracy of taste evaluation in animal models because the in situ drug concentration in the oral cavity cannot be measured accurately. Even if this concentration is measurable, it may still not correlate with 'palatability' and 'acceptable taste' as these perceptions are dependent also on other factors, e.g. the age and taste receptor expression of the animal model used.
The most direct measurement of palatability of a product is to conduct taste evaluation in humans, ideally in the specified pediatric age groups to account for age-related sensitivities towards bitter and sweet tastes (15, 16) . Pediatric taste studies are, however, associated with significant methodological and ethical barriers around participant recruitment. Parents and clinicians may resist a taste trial where a healthy child may accidently ingest a pharmacologically active agent, especially a novel yet-to-be-approved potent agent. On the other hand, parents and clinicians struggling to achieve treatment compliance in a child who requires the intervention of an unpalatable drug may be more inclined to support a clinical trial to evaluate a potentially better tasting product of the drug. In such cases, however, the application of a cross-over study design with placebo or comparator tastant could be unethical.
Children may also be less able than adults to describe taste, and taste trials involving children 5 may have to rely on scales of assessment that are yet to be validated for taste evaluation, e.g. the 5-point facial hedonic scale and visual analogue scales (6) .
Midazolam is a bitter drug that has caused considerable grief in pediatric hospitals. It is widely prescribed as a pre-medication aimed at calming young patients scheduled for surgery and dental procedures. Taste masking of midazolam has been challenging, with both the commercial and extemporaneously compounded oral midazolam syrups known anecdotally for high rejection rates due to poor taste. Rejection of the medicine presents particular difficulties in children who are very anxious or uncooperative in the preoperative setting, e.g. autistic children. In the event of treatment failure, the uncooperative children may have to be physically restrained for the induction of anesthesia, posing, particularly in older children, significant safety risks for the patients, accompanying parent/guardian and attending medical staff.
Our laboratory has developed a novel chewable chocolate-based tablet containing 5 mg of midazolam HCl for use in children. These are small tablets measuring 10 x 5 x 5 mm with 3 score lines to facilitate dose division ( Figure 1A ). The aim of this study was to provide a firstin-kind comprehensive evaluation of the palatability of a pediatric dosage form using a range of methodologies and the midazolam chocolate tablet as a model formulation. We applied the in vitro dissolution test, the rat brief-access taste aversion (BATA) model and a clinical trial involving patients aged 4 -16 years of age to the taste evaluation of the chewable midazolam chocolate tablet. The electronic tongue was excluded because it would involve conducting a dissolution experiment for the midazolam chocolate tablets and analyzing filtered aliquots of the dissolution medium in the E-tongue. The filtered aliquots would not provide an accurate measure of the effectiveness of the chocolate matrix in masking the taste of the released drug.
In this regard, the E-tongue would not offer significant advantages to the dissolution experiments in evaluating the taste of the formulation. A correlation of the in vitro dissolution 6 profile, animal taste aversion profile and pediatric taste scores for the chewable tablet, together with issues associated with each of the methodologies, is discussed in the present study.
Materials and Methods
Midazolam hydrochloride (HCl) (BP grade, Cambrex Profarmaco Milano, Italy) was used as received. All other chemicals were of analytical grade. Deionized water (PSI Water Filters, Launceston, TAS, Australia) was used throughout.
Preparation and storage stability of chocolate-based chewable tablets
Chewable tablets each containing 5 mg of midazolam hydrochloride and measuring 10x5x5 mm were prepared by a melt moulding technique using generally regarded as safe excipients that included dark chocolate (Nestle Australia Ltd, Rhodes, NSW, Australia), hydrogenated castor oil, xanthum gum, polyethylene glycol 1450, and steviol glycosides. All ingredients, except for the dark chocolate, were of pharmaceutical grades (BP or USP) and obtained from registered pharmaceutical suppliers in Australia.
In vitro drug dissolution profiles
In vitro drug dissolution was conducted in triplicates using a paddle rotating speed of 50 rpm (Varian VK 7010 Dissolution Apparatus, Agilent Technologies, Mulgrave, Victoria, Australia). Tablets weighed into separate porcelain crucibles were 'masticated' by crushing with a glass rod into small fragments ( Figure 1B) , and placed into 300 ml of simulated saliva (8 mg/ml sodium chloride, 0.19 mg/ml potassium phosphate monobasic, 2.38 mg/ml sodium phosphate dibasic, pH 6.8) (17) 
In vivo rat taste aversion profile
Ten male Sprague Dawley rats (average weight 719  126 g) previously trained for the rat BATA experiments (18) were used for two independent tasting evaluations. Animal procedures were carried out in accordance with the UK Animals (Scientific Procedures) Act 8
Prior to experiments, the rats were mildly deprived of water for 22 hours but had access to food ad libitum. Taste asked to record how much he/she liked the sample by putting a mark on a separate five-point facial hedonic scale, and whether he/she would be happy to take the sample again if unwell.
Clinical taste evaluation in pediatric patients
The attending parent/guardian was also asked to give a score on a third five-point hedonic scale on how he/she perceived the child's response to the taste of the assigned medication.
Statistical analysis
Rat aversion data were analyzed using the R statistical software (http://www.Rproject.org) after removal of data sets with  1 lick (19) , and the comparison of means was performed using 2-tailed unpaired t-test. Non-parametric Mann-Whitney test and 2-tailed unpaired t-test were applied on the clinical taste evaluation data. With the effect size d=1.0 and α=0.05, this trial has 80% power to detect a difference with 18 children in each group (G*Power 3.1). The gender distribution and the participant's willingness to take the second dose were analyzed using 2-tailed Chi-square test. All statistical analyses were performed with PRISM 6 for Mac (GraphPad software). A P value <0.05 was considered statistically significant. Figure   4A ). This suggests that the rats were unable to effectively detect the bitter drug presented at up to these concentrations. There was a significant drop in licking frequency when the drug concentration was increased to 0.1 mg/mL, and near abandonment of licking when the drug concentration was increased further to 1.0 mg/mL. Dose-response curve for the midazolam HCl standard solutions over the two test days suggests a mean IC50 value of 0.30  0.29 mg/mL ( Figure 4A ). There was no significant difference in the number of licks received between the vehicle and water. Figure 4B shows that, compared to the standard 1 mg/mL midazolam HCl solution, the liquid midazolam chocolate sample prepared by triturating the 5 mg midazolam chocolate tablet in 2 mL of water was significantly better received by the rats. This is despite the chocolate sample having a 2.5 fold higher midazolam HCl content than the standard solution.
Results

HPLC
The mean licking frequencies for the midazolam chocolate sample and placebo chocolate sample were comparable, suggesting that the rats were unable to detect the bitter drug when it was presented in the novel chocolate tablet matrix formulated by our laboratory. In contrast, the proprietary oral syrup prepared by the local hospital, which also contained 2.5 mg/mL midazolam HCl, was less well received.
Preliminary analysis of the clinical study was conducted based on data collected from 38 children aged between 4 to16 years ( Table 1 ). The data was not stratified for patient age due to the small sample size. There were no significant differences in the demographic characteristics of participants in the midazolam chocolate tablet group and the control arm, which received the IV midazolam solution orally.
Non-parametric Mann-Whitney test and 2-tailed unpaired t-test were applied on the clinical taste scores and both tests yielded the same outcome. There was a clear preference for the novel midazolam chocolate tablets (n = 20) compared to the IV midazolam solution administered orally (n = 17; one child in this group was too drowsy to give a score). The largest mean score difference between the chocolate and comparator samples was provided by the child participants ( Figure 5 ). When asked whether they would take the medicine again, 75%
of participants (n=15) 
Discussion
Of the 3 taste evaluation studies conducted for the novel midazolam chocolate tablets, the simplest and cheapest to perform were the in vitro dissolution experiments. There were no requirements for ethics approval and animal/patient recruitment, and consistent data were readily obtained within days. However, the lack of consensual dissolution methodology and simulated salivary fluid to employ (20) has significant implications on a drug with pHdependent aqueous solubility. Midazolam is a weak base (pKa 6.04) (21) . It is soluble in acidified water (>2.5 mg/ml), but the solubility decreased to < 0.1 mg/ml at pH > 5. In our study, the volumes of dissolution media employed were significantly higher than the volume of saliva in the oral cavity. This is to ensure the dissolution experiments could be optimally 13 conducted with the chocolate tablets in the USP dissolution apparatus. Despite the high volume of dissolution media used, drug saturation was apparent within 10 min of introducing the midazolam chocolate tablet into the simulated saliva (pH 6.8). This could underestimate drug release in the oral cavity in vivo. Conversely, the relative ease with which midazolam
HCl dissolved in 500 ml of 0.1 M HCl would overestimate the oral drug level. The typical saliva volume in human is no more than 2 ml (22), but this low volume was difficult to apply in dissolution experiments for the chocolate-based tablets as it rendered the samples too thick to be filtered for HPLC analysis. The chewable midazolam chocolate tablets are not likely to remain in the mouth of patients for longer than 5 min, so the extent of drug released from the tablet into the oral cavity can be predictable from the drug concentrations in the 0 and 5 min aliquot samples. In this study, the sampling time for the dissolution experiments was extended to 60 min to also provide us with an estimate of the peroral drug bioavailability in vivo. There is no validated method to simulate tablet mastication for in vitro drug dissolution studies. In the absence of a defined method, we have improvised a reproducible, if rather crude, method for the chewable chocolate tablets. However, the dissolution data could not be directly correlated to taste aversion without prior knowledge of the taste detection and tolerance thresholds for midazolam in the pediatric patients.
Taste evaluation using the rodent BATA model allowed the test product to be simultaneously evaluated against a range of controls, and provided the in vivo IC50 and taste thresholds for midazolam HCl. On the basis that taste aversion was reflected by a significant reduction in the licking frequency, the detection threshold for the bitter taste of midazolam
HCl would be about 30 g/ml in the rodent model.
Challenges associated with the rodent model included the requirement for animal ethics approval. Rats had to be purchased and trained and, while the trained rats could be re-used over several months, there were on-going agistment costs. Another disadvantage was the 14 inability to administer the solid tablet to the rats with the present lickometer. Instead, the tablet had to be rendered into a liquid, and the concentration of midazolam presented to the rats' oral cavity (2.5 mg/ml) could be higher than if the rats were administered with the chewable tablets.
Animal behavior was also not always predictable. Despite the controlled experimental environment of dim lighting and minimal noise, some rats did become distracted and stop licking the sample presented. A waiting time to first lick of 20 seconds was imposed, and where a sample attracted 0 or 1 lick, whether or not this was due to the rats being distracted or the sample having an unpalatable taste, the data had to be discounted as outliers (possible false negatives) for the final data analysis. To enhance the reliability of data, 10 rats were used and every tastant presented 4 times, resulting in an experiment that took 7h to complete, discounting sample preparation time. There was no scope for automation, unlike the dissolution experiment, although replicate experiments could still be completed within days.
An excellent analysis of the difficulties and precision associated with the BATA method has earlier been reported by our colleagues (18) .
Of the 3 studies conducted, the most direct taste data was obtained from the clinical trial, which also provided an analysis of pharmacodynamic effects in the target pediatric patients.
The facial hedonic scales provided by the children suggested that the chocolate formulation was able to significantly mask the bitter taste of midazolam, as was the finding that 75% of the participants in the test group were willing to take the chocolate tablets again. The facial hedonic scores also suggest that the children were more willing to differentiate between the tastes of the midazolam chocolate tablet and solution compared to their caregivers.
The clinical study was, however, the most expensive to conduct, and it took the longest time. Preclinical in vitro dissolution and animal taste data were required by the hospital ethics committee, and participation was restricted to patients prescribed with midazolam for presurgery sedation. This then exposed the study to the unique dynamics between sick children 15 and their caregivers. For example, a child attempting to exert some control over their condition might refuse a medication or rate it poorly; we had children giving a low score for the midazolam chocolate tablet who had then asked whether they could have a second tablet. We also had a small number of very young children who had insisted on scores based on preferred facial expression on the hedonic scale rather than the taste of the medication. These factors underscore the urgency of validating scoring tools, including the 5-point hedonic scale used in this study, for the taste assessment of pediatric medicines.
A cross-over study design that could have provided more robust comparative taste data was also not possible when the participants required only 1 dose of midazolam prior to surgery.
In addition, the midazolam doses, which were prescribed by attending anesthetists independent of the study, did not always conform to the recommended study dose of 0. to 'Bad') on a 7-point hedonic scale for a commercial midazolam syrup (23) .
The collective in vivo taste data of this study suggest that the novel chocolate-based matrix formulation has the potential to provide an acceptable peroral midazolam product for paediatric (and dysphagic) patients. Chocolate is an important taste masking ingredient, but the matrix also employs other ingredients to enhance its taste masking capacity, and to provide storage stability at ambient temperature. The generic applicability of this chewable matrix to 17 formulate acceptable products of other bitter drugs is currently being investigated in our laboratory.
Conclusion
Harmonized methodologies are urgently required for the taste evaluation and development of novel pediatric medicines. In vitro dissolution data can be rapidly and routinely generated to evaluate the effectiveness of taste masked medicinal products provided the in vivo taste threshold and tolerance concentrations of the drug are known. The latter may be determined using rodent taste aversion studies, which can also provide preliminary taste Hospital for Children. Statistical significance is indicated by *P < 0.05, **P < 0.001, or ***P < 0.0001.
